Precigen(NASDAQ) PGEN

Precigen, Inc. makes gene therapies to treat difficult diseases. Their main medicine helps adults with rare airway tumors. These products help the body's immune system fight infections.

Fighting Disease With Gene Therapy

• Papzimeos: An FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis; generated $53.1 million in revenue in the three-month period ended June 30, 2026.
• AdenoVerse Platform: A technology that uses specific viruses to deliver genetic instructions directly to diseased cells for target proteins.
• UltraCAR-T Platform: A system designed to create personalized cancer treatments at hospitals in only one day.
• Exemplar: A business unit providing genetically engineered miniature swine for medical researchers to study human diseases.

Scaling Up and Branching Out

• Launched Papzimeos in the United States as the first approved therapy for adult RRP following FDA approval on Aug. 14, 2025.
• Submitted a formal marketing application to the European Medicines Agency to expand its lead therapy into European markets.
• Completed enrollment for a Phase 1b clinical study of PRGN-3006 for patients with acute myeloid leukemia.
• Shut down operations at the ActoBio subsidiary in 2024 to focus corporate resources on primary gene therapy programs.

Why Their Tech Is Different

The company uses its proprietary UltraPorator device to manufacture cell therapies overnight at medical centers. This decentralized process aims to reduce costs and ensures patients receive fresh treatments.

Measuring Recent Performance

• Total revenue was $55.0 million in the three-month period ended June 30, 2026, up over 200% year over year.
• Net income reached $20.1 million in the second quarter of 2026, marking the first period of profitability since 2020.
• Research and development expenses fell 36.6% to $7.3 million in the quarter ended June 30, 2026.
• Selling, general and administrative expenses rose 37.9% to $22.2 million in the second quarter of 2026, driven by commercial launch activities.
• Cash, cash equivalents, and investments totaled $38.7 million as of June 30, 2026.

Bottom Line

Precigen has evolved from a research organization into a commercial biopharmaceutical company. Its transition to profitability in 2026 was driven by the first successful launch of its gene therapy products.